PRISM BioLab
PRISM BioLab is a biotechnology company focused on discovering small molecule inhibitors of protein-protein interaction (PPI) targets. They utilize their proprietary PepMetics technology to create orally available drugs for various diseases, including cancer and autoimmune disorders. This technology addresses the challenge of targeting PPIs, previously considered 'undruggable', by mimicking crucial peptide structures.
Funding Round:
Funding Amount: $10.3M
Date: 24-Jan-2024
Investors: Eli Lilly and Company, Santec Holdings Corporation
Markets: Biotechnology, Pharmaceuticals, Drug Discovery
HQ: Tokyo, Tokyo, Japan
Founded: 2006
Website: https://www.prismbiolab.com/
LinkedIn: https://www.linkedin.com/company/prismbiolab-co-ltd
Crunchbase: https://www.crunchbase.com/organization/prism-biolab
Leave a Comment
Comments
No comments yet.